Status:
UNKNOWN
Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB
Lead Sponsor:
Ain Shams University
Collaborating Sponsors:
Cairo University
Menia University
Conditions:
Vitiligo
Eligibility:
All Genders
6-60 years
Phase:
PHASE1
Brief Summary
Vitiligo is a disease in which autoimmunity plays a major role. Multiple treatment options are available, of which narrow-band UVB is a cornerstone, acting through immunosuppression and repigmentation...
Detailed Description
Vitiligo is acquired depigmentation disorder. Several theories were hypothesized for causing vitiligo, of which the autoimmune theory is the most accepted. The main targets of therapy are stabilizati...
Eligibility Criteria
Inclusion
- Active cases of non-segmental vitiligo, VIDA +2 or more.
- All skin types
- Age above 6 years, both sexes.
Exclusion
- Contraindications to NB-UVB ( photosensitive skin disorders, skin malignancy, patients on photosensitizing medications)
- Contraindications to mini-pulse steroid therapy (uncontrolled diabetes or hypertension, peptic ulcer)
- Stable disease (VIDA 0 \& -1) and activity more than 6 months ago (VIDA +1).
- The use of other treatment for vitiligo during the 3 months previous to enrollment.
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04030988
Start Date
November 1 2018
End Date
November 1 2019
Last Update
July 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Abbaseya, Egypt, 00202